29 September 2026
A landmark randomized clinical trial, currently available as a preprint awaiting peer review, challenges decades of clinical practice, suggesting that oseltamivir provides no clinical benefit and is highly likely to increase 90-day mortality in critically ill patients hospitalized with severe influenza.
Evaluating 442 critically ill patients aged 12 years and older with laboratory-confirmed influenza across 18 countries between March 2020 and March 2026, researchers compared a standard 5-day regimen (n=162), an extended 10-day regimen (n=156), and no antiviral therapy (n=124).
Recruitment into both oseltamivir monotherapy arms was halted prematurely after an independent Data Safety Monitoring Board (DSMB) determined that both regimens breached the trial's prespecified threshold for statistical inferiority (<0.2% probability of being the optimal regimen). The trial’s primary endpoint, 90-day all-cause mortality, revealed markedly worse outcomes among patients allocated to the antiviral:
No Antiviral Control: 13.7% mortality (17 of 124 patients).
5-Day Oseltamivir: 19.8% mortality (32 of 162 patients).
10-Day Oseltamivir: 19.4% mortality (30 of 155 patients).
Posterior Bayesian probability analyses [a statistical method that calculates the direct probability that a specific hypothesis is true (e.g., "the drug causes harm" or "the treatment is more effective than no treatment"), given the actual data observed and collected during the trial] estimated a 98.0% and 98.2% probability of harm for the 5-day and 10-day regimens, respectively, relative to supportive care alone. Subgroup evaluations indicated that the risk of harm was particularly pronounced in patients presenting with baseline shock (96.7% probability of harm) and documented bacterial co-infection (97.3% probability of harm). The authors postulated that while oseltamivir inhibits viral neuraminidase, it also interferes with endogenous human host neuraminidases. Preclinical and clinical evidence indicates this cross-inhibition disrupts platelet sialylation, impairs neutrophil migration, and compromises host immune defenses against secondary opportunistic pathogens, notably Aspergillus, cases of which were observed more frequently in the trial's oseltamivir cohort (3.7% vs. 0.8%).
Over a decade ago, rigorous systematic evaluations by the Cochrane Collaboration concluded that oseltamivir offered only marginal clinical benefit in outpatient influenza, shortening the duration of symptoms by roughly 17 hours, while failing to show a statistically verifiable reduction in hospitalizations, pneumonia, or secondary lower respiratory tract complications (1). In parallel, global regulatory authorities, including the U.S. Food and Drug Administration (FDA), mandated safety warnings on Tamiflu package inserts following post-marketing surveillance reports of acute neuropsychiatric adverse events (2). These documented events, observed predominantly in pediatric and adolescent patients, include delirium, hallucinations, agitation, and abnormal behavior resulting in injury and, in rare instances, fatal outcomes.
(Note: These findings have been released as an unreviewed preprint to rapidly disseminate critical safety data to the international clinical and research community; formal peer review is currently pending.)
1. Jefferson et al. (2014). Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Bmj. Apr 9;348.
2. Toovey et al. (2008). Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug safety. Dec;31(12):1097-114.
REMAP-CAP Investigators. (2026). Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial. SSRN Preprint.
